Christopher James Frankenfield, CFO of Xilio Therapeutics XLO, has filed 0 purchases and 2 sales on the open market. Over the past 12 months that comes to a net sale of $4,499. The latest trade was on 01/02.

CF

CF

Christopher James Frankenfield

CFO

Company

Xilio Therapeutics XLO

First filing

23/08/07

Trades

31 trades

Buys / sales

0 / 2

12-month net buying

−$4,499

Last trade

01/02

FollowShare

Trading activity

6 months1 year2 years5 yearsAll

Transactions

Company	Trade type	Traded	Filed	Shares	Price	Value	Holding change
Xilio TherapeuticsXLO	Open-market sale10b5-1 plan	01/02	01/05	7,030 sh	$0.64	$4,499.2	−22.1%
Xilio TherapeuticsXLO	Open-market sale10b5-1 plan	25/01/02	25/01/03	6,954 sh	$0.98	$6,814.92	−35.9%